Congress fast-tracks biosimilar bills to cut drug and insulin costs, while patent, rebate, and reimbursement roadblocks still stall competition. In the span of 8 days this July, lawmakers introduced a ...
Nearly 5000 eyes and nearly 21,000 injections show comparable vision, anatomical, and safety outcomes between biosimilar ...
Aflibercept biosimilar SB15 improved retinal anatomy while preserving vision in both treatment-naïve and switching patients with nAMD, RVO, and DME. Aflibercept 2 mg biosimilar SB15 (Afilivu; Samsung ...
Real-world natalizumab biosimilar switching preserved relapsing-remitting MS outcomes but lowered treatment satisfaction, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results